BIOXIS Pharmaceuticals

BIOXIS Pharmaceuticals is focused on the development and commercialization of advanced regenerative medical products, particularly within the dermatology and medical aesthetics sectors, aiming to enhance patient care and treatment outcomes. Founded in 2010 in Lyon, France, BIOXIS Pharmaceuticals specializes in regenerative medicine. The company has undergone strategic pivots to enhance its product offerings and market reach. Frédéric Bertaïna serves as both the CEO and Founder, bringing extensive experience to the company.

In May 2022, BIOXIS Pharmaceuticals raised EUR 3. 5 million in funding from Juvamed Group, which contributed to their total amount raised of EUR 3. 5 million and led to a current company valuation of EUR 7. 892 million.

BIOXIS Pharmaceuticals focuses on developing and commercializing innovative regenerative medical products tailored for dermatology and aesthetic medicine. Its leading products include 'MTI-12', an ultra-pure chitosan tissular inductor, and 'Cytosial', a monophasic hyaluronic acid matrix. These products target healthcare professionals and facilities, particularly dermatologists and aesthetic practitioners, enhancing tissue regeneration and aesthetic outcomes. For the most recent fiscal year 2023, BIOXIS Pharmaceuticals reported a revenue of EUR 5,202,806.

4 and an EBITDA of EUR -1,805,950. 8. The company generates income through direct B2B sales to healthcare providers, utilizing a pricing strategy that reflects the premium quality of its medical aesthetic products. BIOXIS Pharmaceuticals is planning to launch new products designed for advanced skin treatments, although specific release dates are yet to be disclosed.

The company aims to expand its market presence in Europe and North America by 2024, leveraging the recent funding of EUR 3. 5 million raised in May 2022 to support these initiatives and enhance its product development and distribution capabilities.